Cargando…
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer
The androgen receptor (AR) is a driver of prostate cancer (PCa) cell growth and disease progression. Therapies for advanced PCa exploit AR dependence by blocking the production or action of androgens, but these interventions inevitably fail via multiple mechanisms including mutation or deletion of t...
Autores principales: | Brand, Lucas J., Olson, Margaret E., Ravindranathan, Preethi, Guo, Hong, Kempema, Aaron M., Andrews, Timothy E., Chen, Xiaoli, Raj, Ganesh V., Harki, Daniel A., Dehm, Scott M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414155/ https://www.ncbi.nlm.nih.gov/pubmed/25669987 |
Ejemplares similares
-
A Structure—Activity Relationship Study of Bis-Benzamides as Inhibitors of Androgen Receptor—Coactivator Interaction
por: Lee, Tae-Kyung, et al.
Publicado: (2019) -
Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022) -
Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1
por: Wang, Shuqin, et al.
Publicado: (2022) -
Androgen receptor: Functional roles and facets of regulation in urology
por: Dehm, Scott M., et al.
Publicado: (2020) -
Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
por: Kohli, Manish, et al.
Publicado: (2012)